Active substanceAcetylsalicylic acid + Caffeine + ParacetamolAcetylsalicylic acid + Caffeine + Paracetamol
Similar drugsTo uncover
  • Aquacitramone
    granules inwards 
  • Ascofen-P®
    pills inwards 
    OTISIFARM, OJSC     Russia
  • Kofil®-plus
    pills inwards 
    URALBIOFARM, OJSC     Russia
  • Kofitsil-plus
    pills inwards 
  • Migrenol® Extra
    pills inwards 
  • Citramarin®
    powder inwards 
    MARBIOFARM, OJSC     Russia
  • Citramon P
    pills inwards 
    BIOSINTEZ, PAO     Russia
  • Citramon P
    pills inwards 
  • Citramon P
    pills inwards 
    UPDATE OF PFC, CJSC     Russia
  • Citramon P
    pills inwards 
  • Citramon P
    pills inwards 
  • Citramon P
    pills inwards 
    MEDISORB, CJSC     Russia
  • Citramon P
    pills inwards 
    URALBIOFARM, OJSC     Russia
  • Citramon P
    pills inwards 
    DALHIMFARM, OJSC     Russia
  • Citramon P
    pills inwards 
  • Citramon P
    pills inwards 
    ATOLL, LLC     Russia
  • Citramon P
    pills inwards 
    NGO Farmvilar, OOO     Russia
  • Citramon P Forte
    pills inwards 
    ATOLL, LLC     Russia
  • Citramon Ultra
    pills inwards 
  • Citramon-MFF
    pills inwards 
  • Citrapar®
    capsules inwards 
    BRYNTSALOV-A, CJSC     Russia
  • Excedrine®
    pills inwards 
  • Dosage form: & nbsppills.
    Composition:

    1 tablet contains:

    active substances: acetylsalicylic acid 0.24 g; paracetamol 0.18 g; caffeine (in terms offemine monohydrate) - 0.03 g.

    Excipients: cocoa bean powder -0.0225 g; citric acid monohydraterat 0.0050 g;

    potato starch -0.0615 g; talc 0.0055 g; calcium stearate - 0.0055 g.

    Description:

    Tablets of light brown color with impregnations, flat-cylindrical with a risk and a facet, with a smell of cocoa.

    Pharmacotherapeutic group:analgesic combined.
    ATX: & nbsp

    N.02.B.A.51   Acetylsalicylic acid in combination with other drugs, excluding psycholeptics

    Pharmacodynamics:

    Combined drug.

    Acetylsalicylic acid (ASA) possesses antipyretic and anti-inflammatory effect, relieves pain, improves microcirculation in the focus of inflammation.

    Paracetamol has analgesic antipyretic and extremely weak anti-inflammatory effect.

    Caffeine reduces drowsiness, feeling fatigue, increases mental and physical performance; increases the tone of the vessels of the brain.

    Pharmacokinetics:

    ASA: when ingested absorption is complete. During absorption, it undergoes presystemic elimination in the intestinal wall and systemic in the liver (deacetylated). The resorbed portion is rapidly hydrolyzed by cholinesterases and albumin and nesterase. therefore the half-life is no more than 15-20 minutes. In the body it circulates (75-90% in association with albumin) and is distributed in tissues as an anion of salicylic acid. Time to reach the maximum concentration - 2 hours Metabolized mainly in the liver with the formation of 4 metabolites, found in many tissues and urine. It is excreted by active secretion in the renal tubules in the form of salicylate (60%) and its metabolites. Removal of unchanged salicylate depends on the pH of the urine (with alkalinization of urine increases ionization of salicylates, their reabsorption worsens and the excretion is significantly increased). The rate of excretion depends on the dose: when taking small doses, the half-life period - 2-3 hours, with an increase in the dose may increase to 15-30 hours. In newborns, the elimination of salicylates is much slower than in adults.

    Paracetamol: adsorption is high.

    the maximum concentration is achieved after 0.5-2 hours and is 5-20 μg / ml. Connection with plasma proteins - 15%. Penetrates through the blood-brain barrier. Less than 1 % from the accepted dose of paracetamol taken by the lactating mother penetrates into the breast milk. The therapeutically effective concentration of paracetamol in plasma is achieved with a dose of 10-15 mg / kg. Metabolised in the liver (90-95%): 80% enters the conjugation reaction with glucuronic acid and sulfates with the formation of inactive metabolites; 17% undergoes hydroxylation with the formation of 8 active metabolites, which are conjugated with glutathione with the formation of already inactive metabolites. With a lack of glutathione, these metabolites can block the enzyme systems of hepatocytes and cause their necrosis. In the metabolism also participates isoenzyme CYP2E1. The half-life is 1-4 hours. It is excreted by the kidneys in the form of metabolites, mainly conjugates, only 3 % at unchanged form. In elderly patients, the clearance of the drug decreases and the half-life increases. Caffeine: when ingested absorption is good, occurs throughout the intestine. Absorption occurs mainly due to lipophilicity, and not water solubility.

    Maximum the concentration is reached in 50-75 minutes and is 1.58-1.76 mg / .p. Fast distributed in all organs and tissues organism; easily penetrates blood-brain barrier and placenta.

    The volume of distribution in adults is 0.4-0.6 l / kg, in newborns - 0.78-0.92 l / kg. Communication with blood proteins (albumins) - 25-36%. Metabolism in the liver undergoes more than 90%, in children of the first years of life up to 10-15 %. In adults, about 80% of the dose of caffeine is metabolized to paraxanthin, about 10% - in theobromine and about 4% - in the theophylline, which subsequently are demethylated in monomethylxanthines, and then into methylated uric acids. The elimination half-life in adults is 3.9-5.3 hours (sometimes up to 10 hours). in newborns - 65-130 h (to 4-7 months of life decreases to value as in adults). Excretion caffeine and its metabolites is carried out kidneys (unchanged in adults 1-2%, in newborns - up to 85 %).

    Indications:

    Pain syndrome of mild to moderate severity (of different origins):

    - headache;

    - migraine;

    - toothache;

    - neuralgia;

    - myalgia;

    - arthralgia:

    - algodismenorea.

    Feverish syndrome:

    - in acute respiratory infections (ARI), including with influenza.

    Contraindications:

    Hypersensitivity; erosive and ulcerative lesions of the gastrointestinal tract (in the phase of exacerbation); gastrointestinal bleeding; complete and incomplete combinationBronchial asthma, recurrent nasal polyposis and paranasal sinuses and intolerance to ASA or other non-steroidal anti-inflammatory drugs (including history); hemophilia; hemorrhagic diathesis, hypoprothrombinemia; gantry hypertension; avitaminosis K; renal failure: pregnancy, period lactation; deficit glucose-6-phosphate dehydrogenase; arterial hypertension III degree; severe course of ischemic heart disease; glaucoma; increased excitability; sleep disorders; surgical interventions, accompanied by bleeding: children's age (under 15 years - the risk of developing Reye's syndrome in children with hyperthermia on (background of viral diseases).

    Carefully:Gout, hyperuricemia; peptic ulcer stomach and duodenum, gastrointestinal bleeding (in the anamnesis); concomitant therapy with anticoagulants; elderly age.
    Pregnancy and lactation:

    Application during pregnancy and in the period of lactation is contraindicated.

    Dosing and Administration:

    Inside (during or after eating). Adults and children over 15 years 1-2 tablets 2-3 times a day.The interval between doses should be at least 4 hours. The average daily dose is 3-4 tablets, the maximum daily dose is 8 tablets. The course of treatment is no more than 7-10 days.

    The drug should not be taken more than 5 days as an analgesic drug and more than 3 days - antipyretic (without appointment and supervision of a doctor). Other doses and schedules are prescribed by the doctor.

    Side effects:

    Allergic reactions (including Stevens-Johnson syndrome, Lyell), bronchospasm.

    - From the side of the digestive tract: gastralgia, nausea, vomiting, hepatotoxicity, erosive and ulcerative lesions of the gastrointestinal tract.

    - On the part of the hematopoiesis system: with prolonged use - reduced platelet aggregation, hypocoagulation, hemorrhagic syndrome (epistaxis, bleeding gums, purpura and DR -) -

    - From the cardiovascular system: increased blood pressure, tachycardia.

    - From the central nervous system: at long reception - a giddiness, a headache, infringement of sight, noise in ears, deafness.

    - From the urinary system: nephrotoxicity, with prolonged use - kidney damage with papillary necrosis.

    Perhaps the development of children in the Reye syndrome (hyperpyrexia, metabolic acidosis, disorders of the nervous system and psyche, vomiting, violations of liver function).

    Overdose:

    Symptoms due to ASA: in mild intoxication - nausea, vomiting, gastralgia, dizziness, ringing in the ears; with severe intoxication - retardation, drowsiness, collapse, convulsions, bronchospasm, shortness of breath, anuria. bleeding. encephalopathy, coma. Originally central hyperventilation of the lungs leads to respiratory alkalosis (shortness of breath, choking, cyanosis, sweating): by degree of intoxication progressive paralysis of respiration and dissociation oxidative phosphorylation cause respiratory acidosis. After 1 -2 days, signs of liver damage are identified (liver failure).

    Symptoms caused by paracetamol: during the first 24 hours after administration - pallor of the skin, nausea, vomiting, anorexia, pain in the abdominal area; metabolic acidosis. After 12-48 h - symptoms of impaired liver function. In severe overdose - hepatic failure from progressive encephalopathy, coma, death; acute renal failure with tubular necrosis; arrhythmia; pancreatitis. Hepatotoxic effect in adults is manifested when taking 10 g or more.

    Treatment: gastric lavage, the appointment of adsorbents (Activated carbon); constant monitoring of acid-base state and electrolyte balance; depending on the state of metabolism - the introduction of sodium bicarbonate, sodium citrate or sodium lactate. Increased reserve alkalinity increases the excretion of ASA due to alkalinization of urine. In liver lesions caused by paracetamol - the introduction of specific antidotes; methionine (8-9 hours after overdose). N-acetylcystane (after 12 hours)


    Interaction:

    ASA: enhances the action of heparin, indirect anticoagulants. reserpine, steroid hormones, hypoglycemic agents. Simultaneous use with methotrexate and non-steroidal anti-inflammatory drugs increases the risk of side effects. Reduces the effectiveness of spironolactone, furosemide. antihypertensive drugs, anti-gout agents. Paracetamol: simultaneous use with barbiturates, rifampicin, salicylamide, antiepileptic drugs, other inducers of microsomal liver enzymes promotes the formation of toxic metabolites of paracetamol, affecting liver function.

    Simultaneous reception with ethanol increases the risk of hepatotoxic effects. Metoclopramide accelerates the absorption of paracetamol. Under the influence of paracetamol, the half-life of chloramphenicol increases five-fold. At repeated reception paracetamol can enhance the effect of anticoagulants (coumarin derivatives).

    Caffeine: accelerates the absorption of ergotamine reduces the absorption of calcium preparations, reduces the effect of narcotic and hypnotics.

    At simultaneous application with ß2-adrenomimetics in high doses (salbutamol, fenoterol) increased risk development of hypokatemia, with methylxanthines - their concentration in blood plasma and increases risk of toxic effects.

    Special instructions:

    With continued use of the drug, control of peripheral blood and the functional state of the liver is necessary.

    Because ASA slows blood clotting, the patient, if he is to undergo surgery, must warn the doctor in advance about taking the drug.

    ASA in low doses reduces the excretion of uric acid. In patients with a corresponding predisposition, this can in some cases provoke a gout attack.

    During treatment should be abandoned the use of ethanol (increased risk of gastrointestinal bleeding).

    Effect on the ability to drive transp. cf. and fur:

    One should refrain from driving vehicles and working with other mechanisms, since caffeine, which is part of the drug, can cause a violation of concentration and reaction rates.

    Form release / dosage:

    Pills.

    Packaging:6, 10 tablets into the contour celllessPackaging of packaging paper.

    10 tablets per contour cell packaging from polyvinylchloride film and aluminum foil printed lacqueredpaper or packaging paper.

    For 1, 2 contour mesh packages with instructions for use are placed in a pack of cardboard.

    For 20 contour non-jawed or contour, cell packs with an equal number of instructions for use are placed in a pack of cardboard.

    Contour non-cellular or contour mesh packages with an equal number of instructions for use are placed in a group package.

    Storage conditions:

    In a dry place at a temperature of no higher than 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    4 years.

    Do not use after the expiration date printed on the package.

    Terms of leave from pharmacies:Without recipe
    Registration number:LSR-006922/10
    Date of registration:21.07.2010
    The owner of the registration certificate:UPDATE OF PFC, CJSC UPDATE OF PFC, CJSC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp10.06.2013
    Illustrated instructions
      Instructions
      Up